Cutaneous lupus erythematosus (CLE) is a disfiguring and potentially disabling disease that causes significant morbidity in patients. Antimalarials are an important class of medication used to treat this disease and have been the first-line systemic therapy since the 1950s. Quinacrine, in particular, is used as an adjuvant therapy to other antimalarials for improved control of CLE. Quinacrine is currently unavailable in the USA, which has taken away an important component of the treatment regimen of patients with CLE. This paper reviews the evidence of available local and systemic therapies in order to assist providers in choosing alternative treatments for patients who previously benefited from quinacrine therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577055 | PMC |
| http://dx.doi.org/10.1136/lupus-2020-000430 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Blood DNA virome associates with autoimmune diseases and COVID-19.
Nat Genet
January 2025
Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan.
Aberrant immune responses to viral pathogens contribute to pathogenesis, but our understanding of pathological immune responses caused by viruses within the human virome, especially at a population scale, remains limited. We analyzed whole-genome sequencing datasets of 6,321 Japanese individuals, including patients with autoimmune diseases (psoriasis vulgaris, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pulmonary alveolar proteinosis (PAP) or multiple sclerosis) and coronavirus disease 2019 (COVID-19), or healthy controls. We systematically quantified two constituents of the blood DNA virome, endogenous HHV-6 (eHHV-6) and anellovirus.
View Article and Find Full Text PDFPustular and crusted lesions in systemic lupus erythematosus: A case report.
J Family Med Prim Care
November 2024
Department of Dermatology, Venereology and Leprosy, SRM Medical College and Research Centre, Chengalpattu, Tamil Nadu, India.
Systemic lupus erythematosus (SLE) is the prototype of an autoimmune disease with various manifestations in the skin and several other organs. Subacute cutaneous lupus erythematosus may present with annular and psoriasiform lesions. There have been case reports of pustular lesions in SLE.
View Article and Find Full Text PDFClinical correlations of serum anti-dsDNA immunoglobulin subfamilies in patients with systemic lupus erythematosus (SLE).
Autoimmunity
December 2025
Department of Clinical Immunology & Allergy, Westmead Hospital & ICPMR, Westmead, NSW, Australia.
Systemic lupus erythematosus (SLE) is an extremely heterogenous autoimmune disorder. A key biomarker, the double stranded (ds) DNA autoantibody, provides diagnostic specificity for SLE. We analyzed anti-dsDNA by mass spectrometry (MS) to determine if ascertaining the autoantibody's heavy chain variable region (IGHV) may hold any clinical relevance.
View Article and Find Full Text PDFAn Unusual Presentation of Cutaneous Bullous Lupus.
Cureus
November 2024
Rheumatology, Cooper University Health Care, Camden, USA.
Drug-induced lupus erythematosus (DILE) is an autoimmune reaction that results in symptoms of polyarthralgia, fever, and cutaneous lesions and other manifestations. Several drugs have been documented to cause this disease, including procainamide, isoniazid, methyldopa, penicillamine, and hydralazine. Systemic lupus erythematosus (SLE) manifestations often occur after the patient has been taking the drug without complications for months to years.
View Article and Find Full Text PDFDrug-Associated Risk of Subacute Cutaneous Lupus Erythematosus: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.
J Cutan Med Surg
December 2024
Department of Dermatology, Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!